What is this study trying to find out about dementia and related diseases?

This study aims to develop a model that predicts how neurodegenerative diseases, including various types of dementia and mild cognitive impairment, progress over time. Researchers collect brain imaging, fluid samples, and cognitive data to better understand disease changes. This information may help improve diagnosis and care planning for patients with these conditions.

Who may be eligible for this dementia clinical trial?

Adults aged 30 to 95 with a possible or probable diagnosis of mild cognitive impairment or early dementia may be eligible. Participants need a study partner who contacts them weekly and must be able to complete most study procedures. Both men and women can join. Please review eligibility criteria for more details.

Is there any cost to participate in this dementia clinical trial?

Study-related care, including all assessments and visits, is provided at no cost to participants. Personal expenses like travel may vary and are not guaranteed to be reimbursed. Participants can plan accordingly for any additional costs that might arise.

Actively Recruiting

Age: 30Years - 95Years

All Genders

ID06529744

Predicting Progression in Mild Cognitive Impairment and Early Dementia Using Biomarkers and Modeling in Neurodegenerative Diseases

Led by University Health Network, Toronto · Updated on 2025-11-20

500

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are working to develop a model that can predict how diseases progress in patients with various neurodegenerative conditions, including Mild Cognitive Impairment MCI and different types of dementia such as Alzheimers Disease, Lewy Body Disease, Vascular Dementia, and Frontotemporal Dementia. The study aims to improve diagnosis and forecasting of disease progression to better support patients with early dementia or cognitive impairment. The study will collect and evaluate several types of information from participants, including brain imaging with MRI, samples of blood and cerebrospinal fluid, skin biopsies, and assessments of cognitive ability and behavior through questionnaires. These tests will be done at baseline and during follow-up visits to gather detailed data on disease characteristics and progression. Participants will undergo evaluations at the start of the study, then again at 6 months and 1 year to monitor changes in cognition and other markers. The research team will analyze cognitive performance, DNA methylation from blood samples, neurodegenerative protein levels in fluids and skin, and brain structure and function via MRI. Participants will be monitored over time to provide data that may help predict how their condition changes.

CONDITIONS

Brief Title

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

Who Can Participate

Age: 30Years - 95Years

All Genders

Eligibility Criteria

You may qualify if you...

Possible or probable diagnosis of mild cognitive impairment or early dementia
Age between 30 and 95 years
Have a study partner who has regular weekly contact with the participant
Be able to complete most study procedures as judged by the site investigator

You will not qualify if you...

Unable to complete the majority of assessments as judged by the site investigator
Symptoms believed to be caused by conditions other than neurodegeneration based on investigator's evaluation

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Baseline assessments

Participants undergo various tests including brain MRI, blood and cerebrospinal fluid sampling, skin biopsy, cognitive assessments, and behavioral questionnaires to evaluate their condition.

1 visit (in-person)

Long-term Monitoring

Duration - 1 year

Participants are followed over time with repeated cognitive and biomarker assessments to monitor disease progression.

Visits at 6 months and 1 year (in-person)